Rankings
▼
Calendar
AMRX Q1 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
AMRX
Amneal Pharmaceuticals, Inc.
$4B
Q1 2025 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$695M
+5.5% YoY
Gross Profit
$256M
36.8% margin
Operating Income
$100M
14.4% margin
Net Income
$12M
1.8% margin
EPS (Diluted)
$0.04
QoQ Revenue Growth
-4.8%
Cash Flow
Operating Cash Flow
$7M
Free Cash Flow
-$11M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$3.4B
Total Liabilities
$3.4B
Stockholders' Equity
-$132M
Cash & Equivalents
$59M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$695M
$659M
+5.5%
Gross Profit
$256M
$238M
+7.5%
Operating Income
$100M
-$11M
+1033.8%
Net Income
$12M
-$92M
+113.3%
Revenue Segments
Amneal Specialty Pharma Segment
$108M
50%
Specialty Segment
$108M
50%
← FY 2025
All Quarters
Q2 2025 →